PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
646 episodes - English - Latest episode: 10 days ago - ★★★★ - 8 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Nicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential Care
October 19, 2021 23:00 - 1 hourGo online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor u...
Anthony R. Mato, MD, MSCE - Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies
October 14, 2021 23:00 - 1 hourGo online to PeerView.com/ECV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative ...
Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care
October 13, 2021 23:00 - 1 hourGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. Th...
Jared Weiss, MD - Raising the Bar for Patient Outcomes With Transcription Inhibition and Other New Options in the Treatment Arsenal for SCLC: Rationale, Mechanisms of Action, Latest Data, and Practicalities of Clinical Use in Oncology Practice
October 12, 2021 23:00 - 52 minutesGo online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options a...
Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care
October 12, 2021 23:00 - 28 minutesGo online to PeerView.com/GEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies. Upon completion of this accredited CE activity, participants should be better able to: Describe the biologic rationale for the use of targeted options in the management of advanced biliary cancers, such as those tar...
"Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL"
October 11, 2021 23:00 - 1 hourGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to p...
Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL
October 11, 2021 23:00 - 1 hourGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to p...
Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment
October 11, 2021 23:00 - 51 minutesGo online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, an...
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA/ Kathryn Maples, PharmD, BCOP / Tim J. Peterson, PharmD, BCOP -Making Sense of the New World of Myeloma Care: Pharmacy Perspectives on Novel Antibodies and BCMA CAR-T Therapy
October 08, 2021 23:00 - 1 hourGo online to PeerView.com/WST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of pharmacy experts in multiple myeloma management discusses the latest evidence on novel antibody and CAR-T options and link key take-homes from the data to core aspects of pharmacy practice, from minimizing adverse events/drug interactions to educating patients and staff while addressing other pharmacy considerations. Upon completion...
Stephen V. Liu, MD - Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical
October 06, 2021 23:00 - 1 hourGo online to PeerView.com/DDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The broad implications of the expanding role of cancer immunotherapies in lung cancer necessitate multidisciplinary collaboration, especially in the locally advanced setting where appropriate patient evaluation and selection for immune checkpoint inhibitors (ICIs) along with other multimodal therapies requires input from a medical oncologist, a radiation oncolo...
Sanam Loghavi, MD - Secondary AML Through the Microscope: A Pathology-Informed Guide to Modern Diagnostic and Treatment Principles
October 06, 2021 23:00 - 28 minutesGo online to PeerView.com/SFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses secondary acute myeloid leukemia (AML) as well as the modern tools used in diagnostic assessment that can help facilitate appropriate risk stratification and collaborative treatment decisions so therapies beyond conventional chemotherapy options can be considered. Upon completion of this accredited CE activity, ...
Stephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment
September 29, 2021 23:00 - 1 hourGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory ...
Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC
September 29, 2021 23:00 - 59 minutesGo online to PeerView.com/CBB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs ...
Nina Shah, MD - Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art Care
September 28, 2021 23:00 - 1 hourGo online to PeerView.com/XTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of multiple myeloma experts discuss the recent changes in the multiple myeloma (MM) treatment landscape that have occurred at “warp speed” by focusing on the emergence of novel antibodies, cellular therapy, and targeted strategies across the MM treatment continuum. Throughout, the panelists engage in dedicated Tumor Board sessions desi...
Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy
September 15, 2021 23:00 - 59 minutesGo online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine-...
Ian W. Flinn, MD, PhD - Visualizing the Present and Future of CLL: How Innovative Therapies and State-of-the-Art Combinations Are Transforming Patient Care
September 13, 2021 23:00 - 25 minutesGo online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination stra...
Ruben A. Mesa, MD, FACP - A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
September 10, 2021 23:00 - 37 minutesGo online to PeerView.com/CCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the molecular genetics, cytogenetics, and clinical features of myelofibrosis as well as modern prognostic scoring sys...
Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies
August 31, 2021 23:00 - 54 minutesGo online to PeerView.com/ESW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies. Upon comp...
Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making Strategies to Improve Patient Outcomes
August 17, 2021 23:00 - 46 minutesGo online to PeerView.com/NWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss the diagnosis of cancer-associated VTE, review the latest data and guidelines on currently available treatment options, and suggest strategies for including interprofessional collaboration in routine clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Assess the ...
Suzanne Lentzsch, MD, PhD - A New Treatment Era for Light Chain Amyloidosis: Interprofessional Lessons From a Center of Excellence
July 30, 2021 23:00 - 57 minutesGo online to PeerView.com/KKH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discusses a team-based approach to the management of light chain (AL) amyloidosis. Hear from Suzanne Lentzsch, MD, PhD, Mathew S. Maurer, MD, and Margaret Cuomo, MSN, FNP-C, from the Columbia University Medical Center, as they give insights on diagnostic strategies for AL amyloidosis and as they explore treatment guidelines,...
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors
July 26, 2021 23:00 - 1 hourGo online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitor...
Deborah K. Armstrong, MD - The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice
July 26, 2021 23:00 - 1 hourGo online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhib...
Sumanta Kumar Pal, MD - New Data and Clinical Context: An Update on Renal Cell Carcinoma Care in Early Through Advanced Disease
July 22, 2021 23:00 - 29 minutesGo online to PeerView.com/YFW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses new evidence from ASCO 2021 on the continuing integration of immunotherapy, targeted agents, and novel therapeutics across a wide range of renal cell carcinoma settings. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targ...
Jaffer A. Ajani, MD / Ian Chau, MD, FRCP - Gaining New Ground With Immunotherapy in the Management of Early and Advanced Gastrointestinal Cancers: Translating Progress Into Clinical Practice in Gastric, Esophageal, GEJ, and Colorectal Cancers
July 21, 2021 23:00 - 1 hourGo online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding th...
Jacob Sands, MD - Making the Most of Treatment Advances in SCLC: New Standards, Practicalities of Care, and Hope on the Horizon
July 20, 2021 23:00 - 1 hourGo online to PeerView.com/FJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting...
Sara M. Tolaney, MD, MPH - Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in Advanced and Early HR+ Breast Cancer: Expert Perspectives on CDK4 and 6 Inhibitors and Other Novel Agents
July 20, 2021 23:00 - 1 hourGo online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as a...
Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics
July 20, 2021 23:00 - 1 hourGo online to PeerView.com/GXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Clinical Consults webcast, a panel of experts looks at modern AML therapeutics that have transformed practice in high-risk, good-prognosis, mutation-defined, and post-remission settings (such as TP53-mutant AML, IDH and FLT3 mutation-positive disease, among others). Our experts offer guidance on how disease biology drives treatment decisions and on the ...
Jason J. Luke, MD, FACP / Geoffrey T. Gibney, MD - Building Better Models for Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease
July 16, 2021 23:00 - 1 hourGo online to PeerView.com/GZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two melanoma experts engage in case-based discussions and scientific lecture segments on topics such as the selection of immunotherapy in metastatic disease, best practices for the use of adjuvant or neoadjuvant checkpoint blockade, and how future care will be defined by emerging science on novel immunotherapy combination approaches. Upon comp...
Joyce O’Shaughnessy, MD - Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in the Treatment Arsenal for Triple-Negative Breast Cancer
July 16, 2021 23:00 - 1 hourGo online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited opt...
Sara Hurvitz, MD - Making Progress in Early and Advanced HER2-Positive Breast Cancer: Leveraging HER2-Targeted Therapies and Modern Care Principles to Improve Clinical Outcomes and Health Equity
July 16, 2021 23:00 - 1 hourGo online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need...
Nicola Gökbuget, MD - Achieving Therapeutic Innovation in ALL: Insights on Modern Asparaginase Compounds in Pediatric, AYA, and Adult Patients
July 15, 2021 23:00 - 1 hourGo online to PeerView.com/JPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity features case-based expert discussions on the use of asparaginase in the context of broader innovations in ALL care across pediatric, AYA, and adult patients. Our experts give insights on standard asparaginase compounds, monitoring and management of toxicities, hypersensitivity/silent inactivation, and sequential use of alternati...
William G. Wierda, MD, PhD - New Standards for CLL Care With BTK Inhibitors: Using Evidence to Make Personalized Treatment Choices
July 15, 2021 23:00 - 1 hourGo online to PeerView.com/SYN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView Seminar and Tumor Board activity, CLL experts discuss how BTK inhibitors are changing the treatment landscape for patients with CLL. Find out how these experts make treatment choices for upfront and relapsed disease, factoring safety into the decision to use BTK inhibitors and sequencing strategies. These clinical conversations are supported by...
Matthew S. Davids, MD, MMSc - Pushing Therapeutic Boundaries in CLL: The Convergence of Targeted Therapy, Novel Combinations, and Precision Medicine in Patient Care
July 15, 2021 23:00 - 1 hourGo online to PeerView.com/JWG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populatio...
Toni K. Choueiri, MD - Rethinking the Care of Renal Cell Carcinoma: Expert Perspectives on Novel Agents, Combinations, and Sequencing Therapy
July 12, 2021 23:00 - 1 hourGo online to PeerView.com/GHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In a new CME- and ABIM MOC-certified program on RCC from PeerView and the Kidney Cancer Research Alliance (KCCure), an expert faculty panel will share how to optimally select and sequence treatment regimens across multiple lines of therapy for patients with advanced RCC, talk about new options for resectable RCC, and discuss clinical trials involving novel ther...
Karl D. Lewis, MD - Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management
July 08, 2021 23:00 - 1 hourGo online to PeerView.com/TPR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts in basal cell carcinoma (BCC) discusses the evidence that supports incorporating immunotherapy into existing treatment protocols for advanced BCC. Scientific lectures are linked with practical, case-centered sessions designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards in order to clearly...
Matthew D. Galsky, MD - New and Emerging Therapeutic Strategies in Bladder Cancer: Updates in Early-Stage Disease and Beyond
July 07, 2021 23:00 - 31 minutesGo online to PeerView.com/MHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in genitourinary oncology discusses new and emerging strategies for the management of patients with bladder cancer. Upon completion of this accredited CE activity, participants should be better able to: Review when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across pati...
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease
June 25, 2021 23:00 - 1 hourGo online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, bu...
Steven W. Pipe, MD - Envisioning the Future of Emerging Nonfactor Therapies in Hemophilia A and B: The Art and Science of RNA Interference
June 25, 2021 23:00 - 21 minutesGo online to PeerView.com/WUP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hemophilia explores the evidence supporting novel, emerging hemophilia therapeutics and provides guidance on the implications of the evidence presented for real-world practice. Upon completion of this accredited CE activity, participants should be better able to: Discuss current challenges and new developments in the management of...
George L. Bakris, MD - Recognizing and Treating Hyperkalemia in Patients With Heart Failure and/or Chronic Kidney Disease: An Update for Hospitalists
June 25, 2021 23:00 - 1 hourGo online to PeerView.com/FNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, leading experts explore the benefits and limitations of newer potassium binders, such as patiromer and sodium zirconium cyclosilicate, and share evidence-based strategies for managing hyperkalemia to improve patient outcomes. Upon completion of this accredited CE activity, participants should be better abl...
Shanu Modi, MD - Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast Cancer: Can New HER2-Targeted Therapies Address Unmet Needs and Offer Better Options for Challenging Patient Populations?
June 24, 2021 23:00 - 54 minutesGo online to PeerView.com/FXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, medical oncologists discuss the latest advances in managing patients with HER2-positive breast cancer, including an overview of approved and emerging HER2-targeted therapies, and share perspectives on novel targeted therapies and combinations that may improve outcomes in challenging patient subgroups. In addition, practical guidance is offered...
Sara M. Tinsley, PhD, APRN, AOCN - Therapeutic Advancements in Myelodysplastic Syndromes: Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice
June 24, 2021 23:00 - 1 hourGo online to PeerView.com/EQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS annual meeting, our expert panel discusses tactics on how to maximize clinical outcomes for their lower- and higher-risk patients with myelodysplastic syndromes (MDS), with a focus on current and emerging treatment options. Hear practical insights and real-world case discussions and get informed on key safety and ...
Laura S. Wood, RN, MSN, OCN / Sumanta Kumar Pal, MD - The New Therapeutic Era in Renal Cell Carcinoma: Essentials for Team-Based Patient Care
June 23, 2021 23:00 - 59 minutesGo online to PeerView.com/RYZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Practicum will provide oncology professionals involved in the care of patients with RCC with a strong understanding of how newer therapeutic regimens, such as immune checkpoint inhibitors and new TKIs, fit within the current management paradigm. They will also be offered tools to help them master practical aspects tied to their use...
Ronan J. Kelly, MD, MBA / Siva Raja, MD, PhD, FACS - Immune Checkpoint Inhibitor Therapy for Locally Advanced and Early-Stage Esophageal/GEJ Cancer: The Latest Evidence and Implications for Thoracic Surgeons and the Multidisciplinary Care Team
June 23, 2021 23:00 - 58 minutesGo online to PeerView.com/PSN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As key members of the interdisciplinary care team, thoracic surgeons play an essential role in collaborating and coordinating with their colleagues from other specialties to assess and manage patients with esophageal/GEJ cancer and determine the most appropriate treatment plans based on new evidence inclusive of local and systemic treatment modalities. Thoracic...
Elizabeth A. Raetz, MD / Rachel Rau, MD - Meeting Therapeutic Challenges in Pediatric ALL: Expert Perspectives on the Use of Asparaginase Compounds
June 22, 2021 23:00 - 1 hourGo online to PeerView.com/ZBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert faculty panel focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric acute lymphoblastic leukemia (ALL) therapy by pairing a sample case scenario with a short lecture designed to illustrate the tactics and techniques for addressing hypersensitivity and effectively utilizing available asp...
Lesley Camille Ballance, MSN, FNP-BC / Amy Goodrich, CRNP / Jill Lozensky, RN, BSN, OCN - Changing Times in DLBCL: Oncology Nurse Insight on the Practicalities of Antibody Therapy
June 22, 2021 23:00 - 56 minutesGo online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of ...
Brendon M. Stiles, MD - Immunotherapy as a Game-Changer in Multimodal Management of Locally Advanced and Earlier Stages of Lung Cancer
June 22, 2021 23:00 - 1 hourGo online to PeerView.com/NZQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy currently has a role as consolidation therapy after chemoradiation for patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). Other agents and strategies are being explored in the locally advanced setting as well. Many clinical trials are also investigating the use of immune checkpoint inh...
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation
June 21, 2021 23:00 - 1 hourGo online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in c...
Matthew D. Galsky, MD - The Therapeutic Transformation of Bladder Cancer: Understanding Immune-, Targeted-, and Antibody-Based Models for Patient Care
June 21, 2021 23:00 - 1 hourGo online to PeerView.com/EQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in genitourinary malignancies discusses novel therapies for bladder cancer. Upon completion of this activity, participants should be better able to: Cite the regulatory status and treatment roles of novel therapeutic classes in the management of urothelial cancer, Summarize updated evidence on the use of novel therapies, including im...
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice
June 18, 2021 23:00 - 27 minutesGo online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, ph...
Amy Goodrich, CRNP - Making Modern Treatment Choices in CLL: Oncology Nurse Insights on the Patient Journey and the New Era of Care
June 18, 2021 23:00 - 1 hourGo online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nu...